Tricida (NASDAQ:TCDA) is set to post its quarterly earnings results after the market closes on Thursday, November 14th. Analysts expect Tricida to post earnings of ($0.88) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.
TCDA stock opened at $39.70 on Wednesday. Tricida has a one year low of $19.43 and a one year high of $42.80. The stock has a market capitalization of $1.93 billion, a PE ratio of -8.56 and a beta of 0.85. The company has a debt-to-equity ratio of 0.11, a quick ratio of 14.22 and a current ratio of 14.23. The company has a fifty day moving average of $34.56 and a 200-day moving average of $34.54.
In related news, Director Klaus R. Dr Veitinger sold 4,200 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $33.16, for a total value of $139,272.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert J. Alpern sold 1,832 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $38.98, for a total transaction of $71,411.36. The disclosure for this sale can be found here. Insiders sold a total of 81,926 shares of company stock valued at $2,782,523 in the last 90 days. Company insiders own 66.70% of the company’s stock.
Several analysts have recently commented on the stock. Needham & Company LLC set a $50.00 target price on shares of Tricida and gave the stock a “buy” rating in a research note on Monday, August 12th. Zacks Investment Research upgraded shares of Tricida from a “sell” rating to a “hold” rating in a research note on Thursday, October 10th. ValuEngine upgraded shares of Tricida from a “sell” rating to a “hold” rating in a research note on Friday, October 11th. Finally, Cowen set a $50.00 target price on shares of Tricida and gave the stock a “buy” rating in a research note on Tuesday, October 15th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Tricida currently has an average rating of “Buy” and a consensus target price of $49.60.
Tricida Company Profile
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Featured Article: What are the benefits of a balanced fund?
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.